Malaria:

Recent Updates:

Monograph added.

Indications for ARTESUNATE FOR INJECTION:

Initial treatment of severe malaria.

Limitations of Use:

Not for treating the hypnozoite liver stage forms of Plasmodium and therefore not prevent relapses of malaria due to Plasmodium vivax or Plasmodium ovale.

Adults and Children:

<6months: not established. Give by slow IV bolus inj over 1–2mins. ≥6months: 2.4mg/kg at 0hr, 12hrs, and 24hrs, and thereafter given once daily until able to tolerate oral antimalarial therapy. Complete treatment course with an appropriate oral antimalarial regimen (eg, an 8-aminoquinoline).

ARTESUNATE FOR INJECTION Warnings/Precautions:

Monitor for 4 weeks after treatment for hemolytic anemia. Consider discontinuation if hypersensitivity reactions occur and use alternative treatment. Pregnancy. Nursing mothers.

ARTESUNATE FOR INJECTION Classification:

Antimalarial.

ARTESUNATE FOR INJECTION Interactions:

May be potentiated by strong UGT inhibitors (eg, axitinib, vandetanib, imatinib, diclofenac); monitor. May be antagonized by ritonavir, nevirapine, or strong UGT inducers (eg, rifampin, carbamazepine, phenytoin); monitor for possible reduced efficacy if used concomitantly.

Adverse Reactions:

Acute renal failure requiring dialysis, hemoglobinuria, jaundice.

Generic Drug Availability:

NO

How Supplied:

Single-dose vial (20mL)—1, 4 (w. diluent), 8 (w. diluent)